Dual Antiplatelet Therapy (DAPT) — Comprehensive Summary

1. Definition

DAPT = Aspirin + a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor).
Goal: inhibit platelet adhesion, activation, and aggregation to reduce arterial thrombosis.

---

2. Indications for DAPT

A. Acute Coronary Syndromes

1. STEMI
   • Post-PCI: Aspirin + ticagrelor/prasugrel (preferred) for at least 12 months.
   • Fibrinolysis: Aspirin + clopidogrel.
2. NSTE-ACS
   • Aspirin + ticagrelor (preferred) or clopidogrel/prasugrel (post-angiography).

B. Percutaneous Coronary Intervention (PCI)

1. Drug-Eluting Stent (DES) – chronic coronary syndrome
   • Standard: 6 months DAPT.
   • High bleeding risk (HBR): 1–3 months.
2. DES – ACS context
   • 12 months standard DAPT.
3. Bare-Metal Stent (rare now)
   • 1 month DAPT.

C. Specific conditions

• Post-CABG after ACS: Continue P2Y12 inhibitor up to 12 months.
• Medically managed ACS: Aspirin + ticagrelor for 12 months.
• Left main stenting / bifurcation with 2-stent technique: Often consider extended DAPT (12–36 months) if bleeding risk is low.

---

3. P2Y12 Inhibitors: Comparison

Drug	Type	Onset	Potency	Key Points
Clopidogrel	Prodrug; CYP2C19-dependent	Slow	Moderate	Variability due to genetics; preferred in fibrinolysis and HBR.
Prasugrel	Prodrug	Rapid	High	Contraindicated in prior stroke/TIA; avoid age >75 unless high risk, weight <60 kg needs 5 mg.
Ticagrelor	Direct acting	Rapid	High	Dyspnea & bradyarrhythmias; avoid severe hepatic impairment; improves mortality in ACS (PLATO).

---

4. Duration of DAPT

A. Standard duration

• 12 months for ACS
• 6 months for CCS PCI with DES

B. Short DAPT

• Indicated in high bleeding risk, severe frailty, prior GI bleeding, renal failure, or when on mandatory anticoagulation.
• Regimens:
  • 1 month DAPT → aspirin monotherapy.
  • 1–3 months DAPT → P2Y12 monotherapy (PIONEER AF-PCI, GLOBAL LEADERS, STOPDAPT-2).

C. Prolonged DAPT

• For very high ischemic risk, low bleeding risk:
  • Prior MI, complex PCI, diabetes, PAD.
• PEGASUS-TIMI 54: Ticagrelor 60 mg bid + aspirin beneficial post-MI (1–3 years).

---

5. High Bleeding Risk (ARC-HBR criteria – abbreviated)

Major criteria include:

• Active bleeding
• Severe anemia
• Thrombocytopenia
• Stroke <6 months
• Oral anticoagulation requirement
• Severe CKD on dialysis

HBR = predicted BARC 3–5 bleeding ≥4% at 1 year OR intracranial hemorrhage ≥1%.

---

6. Periprocedural Management

Elective surgery after PCI:

• DES: delay surgery 1–6 months depending on risk.
• Continue aspirin; interrupt P2Y12 (clopidogrel 5 days, prasugrel 7 days, ticagrelor 3 days).

Urgent surgery:

• Continue aspirin; hold P2Y12 if bleeding risk is prohibitive.
• Cangrelor bridging possible in select high-risk PCI (<1 month).

---

7. Key Trials

• CURE: DAPT superior in NSTE-ACS.
• TRITON-TIMI 38: Prasugrel superior to clopidogrel post-PCI in ACS.
• PLATO: Ticagrelor superior to clopidogrel in ACS.
• DAPT Trial: Extended DAPT (30 months) reduces stent thrombosis.
• PEGASUS-TIMI 54: Ticagrelor 60 mg bid beneficial 1–3 years post-MI.
• STOPDAPT-2 / SMART-CHOICE: Short DAPT (1–3 months) feasible.
• TWILIGHT: Ticagrelor monotherapy after 3 months DAPT reduces bleeding.

---

8. DAPT in Special Scenarios

A. Atrial fibrillation requiring OAC + PCI

Preferred:

• OAC + clopidogrel (dual therapy) after 1 week of triple therapy.
• Avoid prasugrel/ticagrelor with OAC unless clear benefit.

B. Chronic kidney disease

• Ticagrelor safe; avoid prasugrel in advanced CKD.

C. Elderly & frail

• Prefer clopidogrel; consider short DAPT.

D. Prior stroke/TIA

• Contraindication to prasugrel.

---

9. Monitoring & Safety

Monitor for:

• Bleeding (GI, intracranial)
• Dyspnea (ticagrelor)
• Bruising
• Platelet function (VerifyNow) in special situations only.

Add-on measures:

• PPIs in high GI-bleed risk
• Avoid NSAIDs
• Counsel on adherence strictly (especially 1st 30 days after stenting)

---

10. Rapid Decision Algorithm (Clinically usable)

1. ACS PCI → Ticagrelor/Prasugrel + Aspirin × 12 months
2. CCS PCI (DES) → Aspirin + P2Y12 × 6 months
3. HBR → 1–3 months DAPT
4. AF + PCI → 1 week triple therapy → OAC + clopidogrel × 6 months
5. Complex PCI / prior MI → consider >12 months DAPT
6. Prasugrel contraindicated → prior stroke/TIA, weight <60, age >75
7. Ticagrelor side effects → dyspnea, bradycardia → switch to clopidogrel/prasugrel

---

DAPT

Advanced FAQs for a Long-Form Pillar Article on DAPT

1. What is the current guideline-recommended minimum duration of DAPT after PCI with contemporary DES?

Most cardiology societies recommend 6 months after PCI for chronic coronary syndromes and 12 months for ACS, unless bleeding risk mandates shorter duration.

2. How does bleeding risk influence decisions on DAPT duration?

High bleeding risk (HBR) patients may qualify for 1–3 months of DAPT, followed by single antiplatelet therapy (SAPT), depending on clinical presentation and stent technology.

3. What is the role of DAPT in medically managed NSTEMI (no PCI)?

DAPT for 12 months with aspirin + P2Y12 inhibitor is typically recommended, provided bleeding risk is acceptable.

4. Which P2Y12 inhibitor is preferred after STEMI treated with primary PCI?

Ticagrelor or prasugrel is preferred over clopidogrel unless contraindicated.

5. When is clopidogrel preferred over prasugrel or ticagrelor?

In patients with advanced age, low body weight, prior stroke/TIA, need for oral anticoagulation, or cost constraints.

6. Is DAPT recommended after elective PCI for stable angina?

Yes, typically 6 months of DAPT, with potential reduction to 3 months in high bleeding risk.

7. Can DAPT be extended beyond 12 months?

Yes, in high ischemic risk patients (e.g., prior MI, complex PCI) with low bleeding risk.

8. What is “complex PCI” in the context of extended DAPT?

Includes left main PCI, long stents (>60 mm), bifurcation with two stents, CTOs, multiple lesions, or ≥3 stents implanted.

9. How is the DAPT Score used?

Scores ≥2 favor extended DAPT, while scores <2 favor discontinuation at 12 months.

10. What is the PRECISE-DAPT score?

A bleeding risk prediction tool; high scores favor shortened DAPT.

11. How does genetic testing influence clopidogrel therapy?

Patients with CYP2C19 loss-of-function alleles have higher risk of MACE and may benefit from ticagrelor/prasugrel.

12. Is a loading dose required when switching P2Y12 inhibitors?

Yes, except when switching from ticagrelor to clopidogrel—which may use either 75 mg or 600 mg depending on timing and bleeding risk.

13. What is the recommended DAPT strategy after CABG for ACS?

Continuation of DAPT for 12 months unless bleeding risk dictates otherwise.

14. Is aspirin still mandatory after PCI?

Yes, aspirin remains foundational unless deprescription is indicated due to bleeding.

15. What is “aspirin-free strategy” in PCI?

Short DAPT (1–3 months) followed by P2Y12 inhibitor monotherapy, studied in several trials (e.g., GLOBAL LEADERS, TWILIGHT).

16. When is prasugrel contraindicated?

History of stroke or TIA, age ≥75 years, or weight <60 kg (relative contraindication).

17. How does DAPT differ in patients undergoing multivessel PCI during STEMI?

They often have higher ischemic risk, so longer DAPT might be beneficial.

18. How soon should DAPT start in STEMI patients receiving fibrinolysis?

Clopidogrel should start immediately; ticagrelor may be introduced later once bleeding risk stabilizes.

19. What is the role of DAPT after bare-metal stent implantation today?

Rarely used; if BMS is used, 1 month of DAPT is generally enough.

20. What is the evidence for DAPT after carotid artery stenting?

Generally 1–3 months of DAPT, followed by aspirin monotherapy.

21. Does chronic kidney disease influence DAPT selection?

CKD increases both bleeding and ischemic risk; decisions must be individualized, often preferring ticagrelor for ACS unless bleeding risk is high.

22. How does DAPT management change in patients requiring oral anticoagulation?

Triple therapy (OAC + DAPT) should be minimized (≤1 week). Dual therapy (OAC + clopidogrel) is preferred long-term.

23. Can DAPT be stopped early in life-threatening bleeding?

Yes, life-threatening bleeding warrants immediate cessation, with careful re-evaluation.

24. What is the recommended DAPT for MINOCA?

Not standardized; aspirin + P2Y12 may be used when plaque rupture is suspected.

25. What is the role of DAPT in spontaneous coronary artery dissection (SCAD)?

Used cautiously; prolonged DAPT is not routinely recommended.

26. What is DAPT’s role in peripheral arterial disease (PAD)?

Short DAPT may be used after endovascular interventions; long-term DAPT is generally not recommended.

27. Is prasugrel safe in patients ≥75 years?

Not preferred; if necessary, a reduced dose (5 mg) may be considered.

28. What are the signs of excessive antiplatelet effect?

Unexplained bruising, mucosal bleeding, epistaxis, melena, or prolonged bleeding from minor cuts.

29. Should DAPT be interrupted for non-cardiac surgery?

If possible, delay surgery until 6 months post-PCI; if urgent, continue aspirin and interrupt P2Y12 inhibitor according to drug half-life.

30. Can DAPT be used in pregnancy?

Aspirin and clopidogrel are relatively safe; prasugrel/ticagrelor lack robust data.

31. What is the risk of stent thrombosis with premature DAPT cessation?

Extremely high, especially in the first 30 days, with mortality up to 45%.

32. What is the difference between ticagrelor 60 mg and 90 mg dosing?

90 mg BID is used in ACS for 12 months;
60 mg BID is preferred for extended DAPT beyond 1 year.

33. Does diabetes influence DAPT duration?

Patients with diabetes may benefit from longer DAPT, particularly after complex PCI.

34. Is DAPT necessary after balloon angioplasty without stent (POBA)?

Often 2–4 weeks of DAPT is sufficient.

35. Is DAPT required after bioresorbable vascular scaffolds?

Yes; due to higher thrombosis risk, 12 months or longer is recommended.

36. Does frailty affect DAPT decisions?

Frailty increases bleeding risk; short DAPT is usually favored.

37. How does anemia affect DAPT management?

Anemia increases bleeding risk; clinicians often shorten DAPT unless ischemic risk is extremely high.

38. What is the role of proton pump inhibitors (PPIs) in patients on DAPT?

PPIs reduce GI bleeding risk and are recommended in many patients on DAPT, especially those with GI bleeding history.

39. How long after DAPT interruption should PCI be performed?

PCI is safest when performed without interrupting DAPT; if unavoidable, aspirin is maintained and P2Y12 restarted as soon as feasible.

40. What biomarkers correlate with bleeding risk during DAPT?

Low hemoglobin, elevated WBC, renal dysfunction, and high D-dimer have been associated with increased bleeding risk.

---

DAPT — 5 Key Clinical Points

1. Standard Duration Depends on Indication

• ACS: 12 months
• Stable CAD: 6 months
• High bleeding risk: consider 1–3 months
  Duration is tailored using ischemic vs bleeding risk scores.

2. Drug Choice Matters

• Ticagrelor or prasugrel preferred in ACS after PCI
• Clopidogrel preferred in elderly, low weight, prior stroke/TIA, or OAC use
• Genotype-guided therapy is rising in adoption

3. Modern Evidence Supports Short DAPT

• Contemporary DES allow 1–3 months DAPT, then P2Y12 monotherapy
• Supported by TWILIGHT, GLOBAL LEADERS, TICO trials
• Reduces bleeding without increasing stent thrombosis

4. Extended DAPT in High-Risk Anatomy

• Prior MI, recurrent ACS
• Complex PCI (CTO, LM, bifurcation, long stents)
• Diabetes or diffuse atherosclerosis
  These patients may derive MACE reduction from prolonged therapy.

5. Bleeding Risk Is the Critical Counterbalance

• Assess using PRECISE-DAPT and ARC-HBR criteria
• Prior GI bleed, CKD, anemia, frailty, anticoagulation → shorter DAPT
• PPI co-therapy reduces GI bleeding risk

---

Dual Antiplatelet Therapy (DAPT): A Complete Clinician’s Guide

Dual Antiplatelet Therapy (DAPT) is a central component of modern cardiovascular care. It reduces ischemic complications such as stent thrombosis, recurrent myocardial infarction, and cardiovascular death. Appropriate patient selection, drug choice, and treatment duration can significantly influence outcomes, especially in high-risk acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) settings.

This comprehensive pillar article consolidates mechanisms, indications, clinical evidence, guideline updates, risk–benefit balancing, duration algorithms, perioperative strategies, and future directions, supported by trial-based insights.

---

1. Overview of Dual Antiplatelet Therapy (DAPT)

1.1 Definition and Concept

Dual Antiplatelet Therapy refers to the combined use of:

• Aspirin (cyclooxygenase-1 inhibitor)
• A P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor)

Together, these agents synergistically inhibit platelet activation and aggregation, thereby reducing thrombotic events, particularly in the context of plaque rupture or foreign surfaces (e.g., stents).

1.2 Mechanism of Action

Aspirin irreversibly inhibits COX-1, suppressing thromboxane A2–mediated platelet activation.

P2Y12 inhibitors block the ADP receptor and downstream platelet amplification mechanisms:

• Clopidogrel – prodrug activated by CYP enzymes (notably CYP2C19).
• Prasugrel – more potent, consistent inhibition, contraindicated in patients with prior stroke/TIA.
• Ticagrelor – reversible, direct-acting agent with faster onset and broader efficacy.

1.3 Historical Evolution of DAPT

Early bare-metal stents (BMS) required only short durations of DAPT.
First-generation drug-eluting stents (DES) increased late thrombosis risk, mandating prolonged therapy.
New-generation DES have significantly lowered thrombosis risk, enabling shorter DAPT in selected patients.

---

2. Indications for DAPT in Cardiovascular Practice

2.1 DAPT in Acute Coronary Syndromes (ACS)

Patients with STEMI, NSTEMI, or unstable angina benefit from DAPT regardless of revascularization strategy.

Key principles:

• Use prasugrel (if PCI and no stroke/TIA) or ticagrelor for ACS
• 12 months of DAPT is considered standard unless contraindicated
• Shortened or extended DAPT depends on ischemic vs bleeding risk profiles

2.2 DAPT After Percutaneous Coronary Intervention (PCI)

Primary indications:

• DES implantation
• High thrombotic risk requiring reinforced antiplatelet coverage
• Complex PCI: long stents, multivessel PCI, left main interventions

Minimum durations:

• ACS PCI – 12 months
• Elective PCI – typically 6 months
• High bleeding risk – 1 to 3 months, depending on stent type

2.3 DAPT After Other Interventions

• Carotid artery stenting – 1–3 months
• Peripheral arterial stenting – varies by vascular bed, commonly 1–3 months
• Fibrinolysis-treated STEMI – aspirin + clopidogrel (14 days to 1 year)

2.4 Special Populations

Patients with atrial fibrillation needing anticoagulation often require careful balancing between:

• Triple therapy (short term)
• Dual therapy (OAC + P2Y12 inhibitor)
• Transition to OAC monotherapy

---

3. Duration of DAPT: Evidence-Based Recommendations

3.1 Standard Duration Recommendations

ESC & ACC/AHA guidelines:

• ACS: 12 months DAPT
• Stable CAD with PCI: 6 months
• High bleeding risk: 1–3 months followed by monotherapy

3.2 Short-Term DAPT (1–3 Months)

Enabled by modern DES and driven by:

• TWILIGHT
• STOPDAPT-2
• SMART-CHOICE
• GLOBAL LEADERS

Benefits:

• Lower bleeding
• Comparable ischemic outcomes in selected patients

Ideal candidates:

• Elderly
• CKD or anemia
• Frail or high-bleeding-risk
• On oral anticoagulants

3.3 Extended DAPT (>12 Months)

Driven by evidence from:

• PEGASUS-TIMI 54
• DAPT Trial
• TRITON-TIMI 38 subgroup analyses

Indication:

• Prior MI within 1–3 years
• High ischemic risk (diabetes, PAD, complex PCI, recurrent MI)
• Low bleeding risk

Extended DAPT reduces major adverse cardiac events but increases bleeding.

---

4. Balancing Ischemic vs Bleeding Risk in DAPT

4.1 Assessing Ischemic Risk

Key factors:

• ACS presentation
• Diabetes mellitus
• CKD
• Diffuse CAD
• Long/overlapping stents
• First-generation DES
• Prior stent thrombosis
• Left-main PCI

4.2 Bleeding Risk Stratification Tools

Two major tools dominate practice:

PRECISE-DAPT Score

• Uses age, creatinine clearance, hemoglobin, WBC, previous bleeding
• High score suggests shortened DAPT

DAPT Score

• Integrates ischemic vs bleeding risk after 12 months
• Score ≥2 → benefit from extended DAPT
• Score <2 → discontinue

4.3 The ARC-HBR Criteria

High bleeding risk defined by:

• Severe anemia
• Thrombocytopenia
• Recent bleeding
• CKD with eGFR <30 mL/min
• Liver disease
• Long-term OAC requirement

---

5. Comparative Overview of P2Y12 Inhibitors

5.1 Clopidogrel

Pros:

• Well tolerated
• Cost-effective
• Suitable for chronic CAD

Cons:

• Variable response due to CYP2C19 polymorphisms
• Less effective in ACS compared to newer agents

5.2 Prasugrel

Pros:

• Potent and consistent inhibition
• Superior to clopidogrel in PCI-treated ACS (TRITON)

Cons:

• Contraindicated in prior stroke/TIA
• Not preferred in elderly or low-weight patients

5.3 Ticagrelor

Pros:

• Superior to clopidogrel (PLATO trial)
• Reduced recurrent MI and cardiovascular mortality
• Works independently of metabolic activation

Cons:

• Dyspnea
• Higher cost
• Twice-daily dosing

---

6. DAPT in Special Clinical Scenarios

6.1 DAPT in STEMI

• Primary PCI: prasugrel/ticagrelor preferred
• Post-thrombolysis: clopidogrel recommended
• Duration: 12 months (extend if high ischemic risk)

6.2 DAPT in NSTEMI

• Ticagrelor or prasugrel preferred
• Early invasive strategy improves outcomes
• 12-month duration standard

6.3 Post-CABG Considerations

• Aspirin is lifelong
• Adding P2Y12 inhibitor may improve graft patency in ACS patients
• Duration typically up to 12 months in ACS

6.4 DAPT in Atrial Fibrillation Patients on Anticoagulation

Principles:

• Minimize triple therapy duration (usually <1 week, maximum 1 month)
• Prefer clopidogrel as P2Y12 inhibitor
• Continue OAC + clopidogrel for 6–12 months
• Then switch to OAC alone

---

7. Perioperative Management of DAPT

7.1 Elective Surgery

Recommended discontinuation:

• Aspirin: continue if possible
• Clopidogrel: stop 5 days prior
• Prasugrel: stop 7 days prior
• Ticagrelor: stop 3 days prior

7.2 Urgent Surgery Post-Stent

If surgery cannot be delayed:

• Proceed with aspirin therapy
• Withhold P2Y12 inhibitor only if bleeding risk outweighs thrombotic risk
• Discuss bridging with IV antiplatelet agents (controversial and patient-specific)

7.3 Postoperative Restart Strategy

• Restart P2Y12 inhibitor ASAP if PCI <6 months
• Restart loading dose if interruption >5 days (except prasugrel in certain scenarios)

---

8. Long-Term DAPT in Secondary Prevention

8.1 Candidates for Extended Ticagrelor Therapy

Based on PEGASUS:

• Prior MI (1–3 years ago)
• Age <75
• Diabetes
• Multivessel disease
• PAD

8.2 Post-MI Risk Reduction

Benefits:

• Reduction in major adverse cardiac events
• Possible mortality benefit

Risks:

• Increased non-fatal bleeding
• Need for careful selection

---

9. DAPT De-escalation, Switching, and Emerging Directions

9.1 De-escalation Strategies

• High bleeding risk patients
• Genotype-guided switching from prasugrel/ticagrelor to clopidogrel
• Guided by trials like TROPICAL-ACS and POPular Genetics

9.2 Platelet Function Testing

Useful in:

• High-risk PCI
• Suspected clopidogrel resistance
• Selected transplant and LVAD candidates

9.3 Future Directions in DAPT

• Personalized antiplatelet regimens
• Integration of AI for ischemic vs bleeding prediction
• Potent agents with lower bleeding risk
• Bioabsorbable stents enabling minimal DAPT durations
• Novel reversible P2Y12 inhibitors under development

---

10. Summary Recommendations for Clinical Practice

• Assess ischemic and bleeding risks in every patient.
• Prefer potent agents (prasugrel or ticagrelor) in ACS unless contraindicated.
• Use standardized scores (PRECISE-DAPT, DAPT score) for duration decisions.
• Short-duration DAPT is safe in many elective PCI cases with modern DES.
• Extended DAPT reduces recurrent MI in select post-MI patients with low bleeding risk.
• Balance therapy carefully in patients requiring anticoagulation.
• Reassess need for therapy periodically and adapt to dynamic risks.

---

dual antiplatelet therapy, DAPT, aspirin clopidogrel, ticagrelor, prasugrel, P2Y12 inhibitor therapy, ACS antiplatelet therapy, PCI antiplatelet regimen, post-PCI DAPT duration, drug-eluting stent DAPT, DES thrombosis prevention, short DAPT strategy, long DAPT strategy, extended DAPT, high bleeding risk PCI, ARC-HBR, PRECISE-DAPT score, DAPT score, P2Y12 monotherapy, aspirin-free strategy, stent thrombosis prevention, complex PCI antiplatelet therapy, left main PCI DAPT, bifurcation PCI DAPT, ACS guideline antiplatelet therapy, STEMI DAPT, NSTEMI DAPT, chronic coronary syndrome DAPT, HBR DAPT, bleeding vs ischemic risk balancing, periprocedural antiplatelet management, DAPT trials, TWILIGHT trial, GLOBAL LEADERS trial, STOPDAPT trial, TICO trial, PEGASUS-TIMI 54, PLATO trial, TRITON-TIMI 38, clopidogrel resistance, CYP2C19 genotype antiplatelet therapy, prasugrel contraindications, ticagrelor dosing, ticagrelor 60 mg, post-CABG antiplatelet therapy, fibrinolysis antiplatelet strategy, MI secondary prevention DAPT, GI bleeding prophylaxis DAPT, PPI with DAPT, aspirin intolerance PCI, antiplatelet therapy elderly, DAPT in CKD, antiplatelet therapy diabetes, triple therapy PCI AF, OAC + DAPT, P2Y12 switch protocol, DAPT after carotid stenting, PAD revascularization antiplatelets

---

antiplatelet dual therapy mechanism, platelet inhibition pathways, aspirin mechanism COX-1 inhibition, P2Y12 receptor blockade, clopidogrel metabolism CYP2C19, poor metabolizer clopidogrel response, stent thrombosis risk factors, restenosis vs thrombosis, early stent thrombosis, late stent thrombosis, very late stent thrombosis, DES polymer technology, contemporary drug-eluting stents, PCI clinical outcomes, ischemic vs bleeding risk tradeoff, high bleeding risk criteria, ARC-HBR definition, PRECISE-DAPT calculation, DAPT score interpretation, prasugrel contraindications stroke, ticagrelor dyspnea side effect, antiplatelet de-escalation strategy, genotype-guided therapy clopidogrel, aspirin desensitization protocol, single antiplatelet therapy transition, P2Y12 monotherapy after PCI, TWILIGHT trial outcomes, STOPDAPT-2 protocol, GLOBAL LEADERS strategy, PEGASUS long-term ticagrelor, PLATO ticagrelor results, TRITON prasugrel outcomes, ACS guideline updates, ACC/AHA DAPT recommendations, ESC DAPT guideline differences, chronic coronary syndrome therapy, bare-metal stent DAPT duration, bioresorbable scaffold thrombosis, CABG post-op antiplatelet plan, fibrinolysis antiplatelet timing, carotid stent antiplatelet regimen, PAD intervention antiplatelets, oral anticoagulant combination therapy, triple therapy duration, DOAC plus antiplatelet combo, perioperative antiplatelet management, urgent surgery after PCI, GI bleeding prophylaxis PPI DAPT, frailty bleeding risk, anemia platelet dysfunction, CKD platelet dysfunction, diabetes pro-thrombotic state, DAPT deprescription algorithm, long-term secondary prevention MI

---

READ MORE

READ MORE